 |
|
|
| |
Aldafermin (NGM282) Produces Greater Anti-Fibrotic Response in Patients with Nonalcoholic Steatohepatitis and Advanced Fibrosis
|
| |
| |
AASLD 2020 Nov 11-16
Guy Neff1, Lei Ling2, Cynthia D. Guy3, Mustafa Bashir4, Angelo H. Paredes5, Juan P. Frias6, Ziad Younes7, James F. Trotter8, Nadege Gunn9, Sam E. Moussa10, Anita Kohli11, Kristin Nelson2, Mildred Gottwald2, William Chang2, Andrew Z. Yan2, Alex M. DePaoli2, Hsiao D. Lieu2 , and Stephen A. Harrison9,12
1Covenant Research, FL; 2NGM Biopharmaceuticals, CA; 3Pathology, Duke University, NC; 4Radiology and Medicine (Gastroenterology), Duke University, NC; 5San Antonio Military Medical Center, TX; 6National Research Institute, CA; 7Gastro One Research, TN; 8Texas Digestive Disease Consultants, TX; 9Pinnacle Clinical Research, TX; 10Adobe Clinical Research, AZ; 11Arizona Liver Health, AZ; 12University of Oxford, United Kingdom
1Covenant Research, FL; 2NGM Biopharmaceuticals, CA; 3Pathology, Duke University, NC; 4Radiology and Medicine (Gastroenterology), Duke University,
NC; 5San Antonio Military Medical Center, TX; 6National Research Institute, CA; 7Gastro One Research, TN; 8Texas Digestive Disease Consultants, TX;
9Pinnacle Clinical Research, TX; 10Adobe Clinical Research, AZ; 11Arizona Liver Health, AZ; 12University of Oxford, United Kingdom
|
| |
|
|
|
|
|
